WebDec 22, 2024 · Vertex will pay privately held biotech Skyhawk Therapeutics $40 million up front in a deal to develop small molecule drugs that can modify RNA and treat unspecified "serious diseases." ... Vertex is the latest to join the fray and team up with Skyhawk, which has already been working with Biogen, Merck & Co., Bristol Myers Squibb and several ... WebJun 1, 2024 · Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta . Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement Cambridge, Mass. and South San Francisco, CA– April 12, …
Research programme: RNA splicing modifiers - Biogen/Skyhawk …
WebFeb 28, 2024 · Biogen is developing small molecule RNA splicing modifiers using Skyhawk Therapeutics' SkySTAR™ (Skyhawk Small molecule Therapeutics for Alternative splicing … WebJan 4, 2024 · A pair of deals announced Friday leaves Biogen Inc. (NASDAQ:BIIB) poised to expand the druggable space of its neurology pipeline. Biogen entered R&D partnerships with targeted protein degradation company C4 Therapeutics Inc. (Cambridge, Mass.) and spliceosome company Skyhawk Therapeutics Inc. (Waltham, Mass.).. Skyhawk uses … canned pbj
Merck, Skyhawk Therapeutics sign collaboration agreement
WebJun 1, 2024 · CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 1, 2024-- Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today announced that the Phase 3 SKYLARK Study of zuranolone, an investigational oral drug being evaluated in women with postpartum depression (PPD), met its primary and all key secondary endpoints. Women … WebJan 8, 2024 · by Iqra Mumal, MSc January 8, 2024. Biogen and Skyhawk Therapeutics have created a strategic partnership that will allow both companies to use Skyhawk’s SkySTAR technology platform for the ... WebJan 4, 2024 · - Biogen made a one-time upfront $74 million payment to Skyhawk for research services and an exclusive license to therapeutic candidates for multi... fix pen ink flow